Boswellia for Dogs: Does It Work for Joint Health?

Over the years, Boswellia serrata has become one of the options cited by owners keen to support their dog's mobility. A resin long used in human herbal medicine, it is now found in many joint supplements for animals.

But behind this growing trend, one question keeps coming up: what do we really know about its effectiveness in dogs?

This article offers a clear, honest reading of the available scientific data, away from marketing promises, based exclusively on published scientific literature.

What is Boswellia serrata?

Boswellia serrata is a tree native to India, known for the aromatic resin it releases when its bark is incised. This resin, used for centuries in Ayurvedic medicine, was traditionally employed to ease joint discomfort and support mobility.

Harvesting remains artisanal: small incisions are made in the trunk, the sap flows out, hardens into amber droplets, then is collected and dried. This resin contains several active molecules, including boswellic acids, which are now at the centre of modern research.

To be used as a supplement, the resin is ground, purified, and then extracted (often with a water/alcohol mixture) to obtain a standardised extract, as the concentration of active compounds can vary greatly depending on the age of the tree, the season, or the growing region.

It is these standardised extracts, and not raw resin, that are studied to assess their potential in joint disorders.

Boswellic acids: the active molecules of interest

Boswellic acids are the most studied components of Boswellia.
Among them, AKBA (acetyl-11-keto-β-boswellic acid) is the best-documented molecule, known for its ability to modulate the 5-lipoxygenase (5-LOX) pathway, involved in the synthesis of pro-inflammatory leukotrienes.

Their concentration depends heavily on:

• the tree's growing region,
• the harvesting method,
• the extraction process,
• and above all, standardisation.

This is why two Boswellia extracts can differ greatly in composition, even if they bear the same name.

Boswellia supplements: highly variable forms

On the market, several types of products are available:

• Resin powders (non-standardised, highly variable from batch to batch)
• Standardised dry extracts (the most widely used in human clinical trials)
• Phytotherapeutic blends where Boswellia is combined with other plants (turmeric, devil's claw, ginger…)
• Combined formulas for animals, often in the form of tablets, chews, or powders

In practice, these supplements differ in their boswellic acid content, the presence or absence of standardised AKBA, the dosage form (powder, tablet, chew, liquid), and bioavailability.

Why is there interest in joints?

If Boswellia is studied in the context of joints, it is mainly because of its boswellic acids, which interact with several inflammatory pathways involved in pain and locomotor stiffness.

An effect on the 5-LOX pathway: reducing leukotriene formation

Boswellic acids, especially AKBA, are known to inhibit the 5-lipoxygenase (5-LOX) enzyme. 5-LOX acts like a "conductor" for producing leukotrienes, molecules involved in inflammatory processes.

In other words:

less 5-LOX activity = fewer leukotrienes = a theoretical reduction in local inflammation.

This mechanism explains why Boswellia is often presented as a "natural anti-inflammatory" ingredient.

A potential effect on certain pro-inflammatory cytokines

Several in vitro studies show modulation of molecules produced during inflammatory processes, such as IL-1β, TNF-α, and MMP (matrix metalloproteinases).

These molecules are involved in the progressive degradation of cartilage in joint disorders.

When a joint becomes sensitised, the body releases cytokines (IL-1β, TNF-α…).
They act like "alarm signals": they amplify inflammation and activate enzymes (MMP) that damage joint tissues.

Boswellic acids appear to dampen this alarm signal, which could slow inflammatory processes.

What do studies actually show?

The literature on Boswellia varies greatly depending on the species studied. Human data are relatively numerous and structured. Veterinary data, however, remain limited, often dated, and above all carried out using plant mixtures. To understand what can reasonably be expected for dogs, it is necessary to distinguish between the two types of studies.

Studies conducted in humans

A review published in Phytotherapy Research describes a significant reduction in pain and an improvement in joint function after administration of a standardised Boswellia extract. The authors also highlight an improvement in walking time and a reduction in analgesic use in some trials. These clinical results are consistent with mechanisms identified in the laboratory.

Another study, published in the Journal of Inflammation Research confirms that AKBA exerts selective inhibition of 5-lipoxygenase, an enzyme involved in leukotriene synthesis. The authors highlight a decrease in the production of pro-inflammatory mediators (including IL-1β) and a reduction in the expression of metalloproteinases involved in cartilage degradation. These findings support the hypothesis of an effect that is both anti-inflammatory and potentially chondroprotective.

Additional studies report similar results and confirm the good long-term tolerability of standardised extracts. The improvements observed mainly concern pain, stiffness and certain functional parameters.

It should be noted, however, that the extracts used in these trials are standardised according to precise methods, which is not always the case for commercially available products. Furthermore, these results cannot be directly applied to dogs due to significant differences in metabolism, bioavailability, and administration protocols.

Studies conducted in dogs

Conversely, veterinary data specifically concerning dogs with joint disorders are far less numerous. Available studies have all been carried out using formulations combining Boswellia with other plants or nutrients, which constitutes the main methodological limitation.

A recent publication by EFSA examines the effect of a mixture containing Boswellia, curcumin, and several antioxidants in dogs with chronic locomotor disorders. Clinical assessments show a decrease in pain scores and improved ease of movement, but the formulation combines many active compounds, which prevents any conclusion about Boswellia's specific contribution.

Another study published in the scientific journal Frontiers analyses an antioxidant formula including Boswellia and shows a reduction in certain inflammation biomarkers. However, the authors emphasise the impossibility of determining which ingredient is responsible for these changes, and the relationship between these biochemical changes and clinical improvement is not established.

Overall, available veterinary studies describe modest but consistent improvements in mobility or joint comfort. However, none of them uses Boswellia in isolation, which considerably limits the scope of the conclusions.

Can you give Boswellia to a dog with arthritis?

With current knowledge, Boswellia cannot be recommended as a reliable solution for a dog's joints. No veterinary study has assessed its effectiveness when used on its own, and the few available studies only concern plant mixtures, which does not allow firm conclusions. Human data confirm an anti-inflammatory potential, but they are not transferable to dogs.

Boswellia can therefore be considered as an adjunct, but must not replace validated approaches in dogs, notably weight management, appropriate physical activity, and supplements whose effectiveness is better established, such as omega-3 EPA and DHA. Any use should be discussed with a veterinarian.

Conclusion

Boswellia serrata holds a particular place in modern phytotherapy, supported by several human studies highlighting genuine anti-inflammatory potential. In humans, some studies show an improvement in pain and joint function, results consistent with mechanisms described in the laboratory.

In dogs, however, scientific data remain very limited. Available studies all use mixtures combining Boswellia with other plants or nutrients, which does not allow its specific effect to be isolated. No publication currently demonstrates that a Boswellia extract used on its own improves mobility or reduces joint-related symptoms in dogs.

In practice, Boswellia can be considered as complementary support, but it is not a solution whose effectiveness is proven. Any use of Boswellia should be discussed with a veterinarian so that it fits appropriately into the dog's overall care plan.

Scientific references

• Umar S, Umar K, Sarwar AH, Khan A, Ahmad N, Ahmad S, Katiyar CK, Husain SA, Khan HA. Boswellia serrata extract attenuates inflammatory mediators and oxidative stress in collagen induced arthritis. Phytomedicine. 2014 May 15;21(6):847-56. doi: 10.1016/j.phymed.2014.02.001. Epub 2014 Mar 22. PMID: 24667331.
• Umar S, Umar K, Sarwar AH, Khan A, Ahmad N, Ahmad S, Katiyar CK, Husain SA, Khan HA. Boswellia serrata extract attenuates inflammatory mediators and oxidative stress in collagen induced arthritis. Phytomedicine. 2014 May 15;21(6):847-56. doi: 10.1016/j.phymed.2014.02.001. Epub 2014 Mar 22. PMID: 24667331.
• Dalmonte T, Andreani G, Rudelli C, Isani G. Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Phytother Res. 2024 Dec;38(12):5672-5689. doi: 10.1002/ptr.8336. Epub 2024 Sep 23. PMID: 39314013; PMCID: PMC11634824.
• Kumar, B., Ghaytidak, A. B., Pandey, A. K., Somepalli, R. R., Sarda, P., Raychaudhuri, S. P., & Rokkam, M. P. (2024). A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study. Journal of the American Nutrition Association, 44(5), 375–386. https://doi.org/10.1080/27697061.2024.2438894
• Karlapudi, V., Sunkara, K. B., Konda, P. R., Sarma, K. V., & Rokkam, M. P. (2022). Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study. Journal of the American Nutrition Association, 42(2), 159–168. https://doi.org/10.1080/07315724.2021.2014370
• Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019 May;33(5):1457-1468. doi: 10.1002/ptr.6338. Epub 2019 Mar 6. PMID: 30838706; PMCID: PMC6681146.
• Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 17;20(1):225. doi: 10.1186/s12906-020-02985-6. PMID: 32680575; PMCID: PMC7368679.
• Stabile M, Fracassi L, Lacitignola L, Garcia-Pedraza E, Girelli CR, Calculli C, D'Uggento AM, Ribecco N, Crovace A, Fanizzi FP, Staffieri F. Effects of a feed supplement, containing undenatured type II collagen (UC II®) and Boswellia Serrata, in the management of mild/moderate mobility disorders in dogs: A randomized, double-blind, placebo controlled, cross-over study. PLoS One. 2024 Oct 30;19(10):e0305697. doi: 10.1371/journal.pone.0305697. PMID: 39475935; PMCID: PMC11524509.
• Zapata A, Fernández-Parra R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals (Basel). 2023 Feb 27;13(5):870. doi: 10.3390/ani13050870. PMID: 36899726; PMCID: PMC10000124.
• EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Bampidis V, Azimonti G, Bastos ML, Christensen H, Fašmon Durjava M, Kouba M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Edoardo Villa R, Woutersen R, Brantom P, Chesson A, Westendorf J, Manini P, Pizzo F, Dusemund B. Safety and efficacy of a feed additive consisting of an extract of olibanum from Boswellia serrata Roxb. ex Colebr. for use in dogs and horses (FEFANA asbl). EFSA J. 2022 Mar 7;20(3):e07158. doi: 10.2903/j.efsa.2022.7158. PMID: 35281639; PMCID: PMC8900119.
• Miscioscia E, Shmalberg J, Scott KC. Measurement of 3-acetyl-11-keto-beta-boswellic acid and 11-keto-beta-boswellic acid in Boswellia serrata Supplements Administered to Dogs. BMC Vet Res. 2019 Aug 1;15(1):270. doi: 10.1186/s12917-019-2021-7. PMID: 31370899; PMCID: PMC6670232.
• Martello E, Bigliati M, Adami R, Biasibetti E, Bisanzio D, Meineri G, Bruni N. Efficacy of a dietary supplement in dogs with osteoarthritis: A randomized placebo-controlled, double-blind clinical trial. PLoS One. 2022 Feb 16;17(2):e0263971. doi: 10.1371/journal.pone.0263971. PMID: 35171954; PMCID: PMC8849458.
• Maxim Moreau, Bertrand Lussier, Jean-Pierre Pelletier, Johanne Martel-Pelletier, Christian Bédard, Dominique Gauvin, Eric Troncy, A medicinal herb-based natural health product improves the condition of a canine natural osteoarthritis model: A randomized placebo-controlled trial, Research in Veterinary Science, Volume 97, Issue 3, 2014, Pages 574-581, ISSN 0034-5288, https://doi.org/10.1016/j.rvsc.2014.09.011.
• Caterino C, Aragosa F, Della Valle G, Costanza D, Lamagna F, Piscitelli A, Nieddu A, Fatone G. Clinical efficacy of Curcuvet and Boswellic acid combined with conventional nutraceutical product: An aid to canine osteoarthritis. PLoS One. 2021 May 28;16(5):e0252279. doi: 10.1371/journal.pone.0252279. PMID: 34048452; PMCID: PMC8162585.

This article was written by the R&D team at Laboratoire Sensilia, experts in animal nutrition.